Synopsis:
Anthem Biosciences Limited reports 60% YoY revenue growth and a 65% YoY net profit surge in Q1 FY26 results.
This Pharma Stock, engaged in global contract research, development, and manufacturing for pharmaceuticals and biologics, specializing in drug discovery, process development, and innovative therapeutic platforms, jumped 9 percent after the company reported strong June quarterly results with a 65 percent YoY increase in net profit.
With a market capitalization of Rs. 45,917.24 crores, the share of Anthem Biosciences Limited has reached an intraday high of Rs. 820 per equity share, rising nearly 8.65 percent from its previous day’s close price of Rs. 754.70. Since then, the stock has retreated and is currently trading at Rs. 817 per equity share.
Q1 FY26 Result Walkthrough
Coming into the quarterly results of Anthem Biosciences Limited, the company’s consolidated revenue from operations increased by 59.55 percent YOY, from Rs. 338.59 crore in Q1 FY25 to Rs. 540.21 crore in Q1 FY26, and grew by 11.80 percent QoQ from Rs. 483.20 crore in Q4 FY25. Anthem Biosciences Limited generated 83.8 percent of its revenue from CRDMO sales and 16.2 percent from Specialty Ingredients sales in Q1 FY26.
In Q1 FY26, Anthem Biosciences Limited’s consolidated net profit increased by 64.83 percent YOY, reaching Rs. 135.79 crore compared to Rs. 82.38 crore during the same period last year. As compared to Q4 FY25, the net profit has increased by 64.35 percent, from Rs. 82.62 crore. The basic earnings per share increased by 65.31 percent and stood at Rs. 2.43 as against Rs. 1.47 recorded in the same quarter in the previous year, 2025.
Company Overview
Anthem Biosciences Limited is a Bangalore-based Contract Research and Development Manufacturing Organization (CRDMO) founded in 2006. The company provides a broad range of services focused on drug discovery, development, and manufacturing for pharmaceutical, biotechnology, specialty chemical, agricultural chemical, and material science companies globally.
Anthem Biosciences specializes in organic synthesis, process development, analytical chemistry, discovery biology, and regulatory compliance. The company provides end-to-end solutions for NCE and NBE programs, leveraging platforms like RNA interference, ADCs, peptides, lipids, and oligonucleotides to accelerate drug development from discovery to commercialization.
Anthem Biosciences Limited employs 2,149 people, including 1,045 scientific staff. The company has a custom synthesis capacity of 324 kiloliters and a fermentation capacity of 142 kiloliters as of June 2025.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma stock jumps 9% after reporting strong June quarter results appeared first on Trade Brains.